Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Completed · Phase 4 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.

Key facts

Study ID: NCT02371980
Run by: Takeda
People needed: 1106
Starts: 2015-02-10
Expected to finish: 2019-04-25
Last updated by the study team: 2021-01-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Suffers from recurrent major depressive disorder (MDD) as the primary diagnosis according to Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria (classification code 296.3x), and the current episode is confirmed by the Mini International Neuropsychiatric Interview (MINI).
Reported duration of the current episode is ≥8 weeks and ≤18months.
Had at least 2 other major depressive episodes (MDEs) before the current episode.
Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline I visits.
Is a man or woman aged 18 to 75 years, inclusive.
A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent throughout the duration of the study and for 30 days after the last dose.

You may not qualify if…

Has received any investigational compound within 30 days prior to screening or 5 half-lives prior to screening, whichever is longer.
Has previously or is currently participating in this study.
Has participated in 2 or more clinical studies in the year prior to screening, or has participated in a clinical trial for a psychiatric condition that is exclusionary per this protocol.
Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
Has one or more of the following:
Any current psychiatric disorder which is the primary focus of treatment other than MDD as defined in the DSM-IV-TR, and assessed by the MINI.
Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder (OCD), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least 3 months from the day of screening (Participant must also have negative urine drug screen at Screening and Baseline I.)
Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator.
Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
Any Axis II disorder as defined by DSM-IV-TR that might compromise the study.
The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
Has a history of lack of response to previous adequate treatment with vortioxetine for any MDD episode with adequate treatment considered to be known dose of vortioxetine in the approved recommended dose range for at least 6 weeks duration.
Has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
Has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
Has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.
Has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.
Note: For the purposes of this protocol fibromyalgia, obstructive sleep apnea, chronic pain diagnosis, and morbid obesity (BMI of > 40) are considered unstable due to the potential impact on assessment of the primary endpoint.
Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
Has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:
A serum creatinine value >1.5 times the upper limits of normal (ULN).
A serum total bilirubin value >1.5 xULN.
A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 xULN.
Has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known stable diabetes are not excluded.

Where it is running

SW Biomedical Research, LLC — Tucson, Arizona, United States
CNS Research Science, Inc. — Cerritos, California, United States
Collaborative Neuroscience Network, LLC — Garden Grove, California, United States
Irvine Center for Clinical Research, Inc. — Irvine, California, United States
Synergy Clinical Research of Escondido — Lemon Grove, California, United States
Pharmacology Research Institute — Los Alamitos, California, United States
Pacific Institute of Medical Research — Los Angeles, California, United States
CNRI - Los Angeles, LLC — Pico Rivera, California, United States
CNRI - San Diego, LLC — San Diego, California, United States
Artemis Institute for Clinical Research, LLC — San Diego, California, United States
University of California San Diego Medical Center — San Diego, California, United States
Pasadena Research Institute — San Gabriel, California, United States
Collaborative Neuroscience Network, LLC — Torrance, California, United States
Research Center for Clinical Studies, Inc. — Norwalk, Connecticut, United States
CNS Clinical Research Group — Coral Springs, Florida, United States
Gulfcoast Medical Research Center, LLC — Fort Myers, Florida, United States
MD Clinical — Hallandale, Florida, United States
Indago Research & Health Center, Inc. — Hialeah, Florida, United States
Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida, United States
Meridien Research — Maitland, Florida, United States
Sarkis Clinical Trials - Parent — Ocala, Florida, United States
Clinical Neuroscience Solutions, Inc. — Orlando, Florida, United States
Stedman Clinical Trials, LLC — Tampa, Florida, United States
Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach — West Palm Beach, Florida, United States
NoesisPharma — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.